AU2021275292A1 - Pharmaceutical for treating fatty liver diseases - Google Patents
Pharmaceutical for treating fatty liver diseases Download PDFInfo
- Publication number
- AU2021275292A1 AU2021275292A1 AU2021275292A AU2021275292A AU2021275292A1 AU 2021275292 A1 AU2021275292 A1 AU 2021275292A1 AU 2021275292 A AU2021275292 A AU 2021275292A AU 2021275292 A AU2021275292 A AU 2021275292A AU 2021275292 A1 AU2021275292 A1 AU 2021275292A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- pharmaceutical composition
- fatty liver
- liver disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020089196 | 2020-05-21 | ||
| JP2020-089196 | 2020-05-21 | ||
| JP2020134338 | 2020-08-07 | ||
| JP2020-134338 | 2020-08-07 | ||
| PCT/JP2021/019088 WO2021235508A1 (ja) | 2020-05-21 | 2021-05-20 | 脂肪性肝疾患の治療用医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021275292A1 true AU2021275292A1 (en) | 2022-12-15 |
Family
ID=78707930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021275292A Abandoned AU2021275292A1 (en) | 2020-05-21 | 2021-05-20 | Pharmaceutical for treating fatty liver diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12521375B2 (https=) |
| EP (1) | EP4154880A4 (https=) |
| JP (1) | JP7820294B2 (https=) |
| KR (1) | KR20230013126A (https=) |
| CN (1) | CN115666558A (https=) |
| AU (1) | AU2021275292A1 (https=) |
| CA (1) | CA3182134A1 (https=) |
| MX (1) | MX2022014553A (https=) |
| TW (1) | TW202207919A (https=) |
| WO (1) | WO2021235508A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4434520A4 (en) | 2021-11-19 | 2025-10-29 | Shionogi & Co | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523225A (ja) | 2000-12-26 | 2004-08-05 | リサーチ ディベロップメント ファンデーション | 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２ |
| US6548738B2 (en) | 2000-12-26 | 2003-04-15 | Research Development Foundation | ACC2-knockout mice and uses thereof |
| US20110009443A1 (en) * | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| WO2011058474A1 (en) | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| BR112013010310A2 (pt) | 2010-10-29 | 2016-11-29 | Pfizer | inibidores de acetil-coa carboxilase de lactama n1/n2 |
| LT2776038T (lt) | 2011-11-11 | 2018-04-25 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| JP6205152B2 (ja) | 2013-03-25 | 2017-09-27 | サイプレス セミコンダクター コーポレーション | シリアル通信システム、受信装置およびシリアル通信方法 |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| JP2016079168A (ja) | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| EA201892201A1 (ru) * | 2016-03-30 | 2019-03-29 | Женфит | Неинвазивная диагностика неалкогольного стеатогепатита |
| US11541046B2 (en) | 2017-06-30 | 2023-01-03 | Quixgen, Inc. | Spirolactone compounds |
-
2021
- 2021-05-20 US US17/926,273 patent/US12521375B2/en active Active
- 2021-05-20 AU AU2021275292A patent/AU2021275292A1/en not_active Abandoned
- 2021-05-20 CA CA3182134A patent/CA3182134A1/en active Pending
- 2021-05-20 KR KR1020227044828A patent/KR20230013126A/ko not_active Withdrawn
- 2021-05-20 WO PCT/JP2021/019088 patent/WO2021235508A1/ja not_active Ceased
- 2021-05-20 JP JP2022524526A patent/JP7820294B2/ja active Active
- 2021-05-20 MX MX2022014553A patent/MX2022014553A/es unknown
- 2021-05-20 EP EP21808650.2A patent/EP4154880A4/en active Pending
- 2021-05-20 CN CN202180035760.4A patent/CN115666558A/zh active Pending
- 2021-05-21 TW TW110118449A patent/TW202207919A/zh unknown
-
2025
- 2025-12-09 US US19/413,251 patent/US20260091022A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260091022A1 (en) | 2026-04-02 |
| JPWO2021235508A1 (https=) | 2021-11-25 |
| JP7820294B2 (ja) | 2026-02-25 |
| KR20230013126A (ko) | 2023-01-26 |
| CA3182134A1 (en) | 2021-11-25 |
| US12521375B2 (en) | 2026-01-13 |
| CN115666558A (zh) | 2023-01-31 |
| TW202207919A (zh) | 2022-03-01 |
| EP4154880A1 (en) | 2023-03-29 |
| EP4154880A4 (en) | 2024-06-05 |
| MX2022014553A (es) | 2022-12-15 |
| WO2021235508A1 (ja) | 2021-11-25 |
| US20230210822A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3012663T3 (en) | Glp-1r receptor agonist compound and use thereof | |
| CN106117193B (zh) | 新的杂环衍生物及其在神经性疾病治疗中的应用 | |
| AU2020378407B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
| KR102612176B1 (ko) | Mgat2 저해 활성을 갖는 축합환 유도체 | |
| EP3805220B1 (en) | Polycyclic carbamoylpyridone derivatives for the treatment of hiv | |
| KR20210005222A (ko) | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 | |
| RU2734261C2 (ru) | Необязательно конденсированные гетероциклилзамещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний | |
| KR20210006407A (ko) | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 | |
| US20260091022A1 (en) | Pharmaceutical composition for treating fatty liver disease | |
| US20260098031A1 (en) | Monocyclic compound having glp-1 receptor agonist activity | |
| JP2020111571A (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 | |
| EP4251273B1 (en) | Phthalazine derivatives as p2x3 inhibitors | |
| BR112021012428A2 (pt) | Derivado de dihidropirazolopirazinona tendo atividade inibitória de mgat2 | |
| US20250041279A1 (en) | Therapeutic medicine for heart disease or skeletal muscle disease | |
| WO2017110841A1 (ja) | Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体 | |
| HK40082231A (en) | Pharmaceutical for treating fatty liver diseases | |
| CN116354961A (zh) | 生长抑素受体5拮抗剂及其药物组合物及用途 | |
| CN109651395B (zh) | 一种可靶向降解fkbp12及12.6的化合物及其制备方法和应用 | |
| RU2800292C2 (ru) | Химические соединения | |
| HK40093123A (en) | Polycyclic carbamoylpyridone derivatives for the treatment of hiv | |
| HK40059861A (en) | Fused ring derivative having mgat-2 inhibitory activity | |
| CN119504808A (zh) | 化合物、其制备方法及用途 | |
| HK40041697B (en) | Polycyclic carbamoylpyridone derivatives for the treatment of hiv | |
| EA047250B1 (ru) | Полициклическое производное карбамоилпиридона | |
| BR112020006456A2 (pt) | compostos químicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |